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Background and Objective: Rapidly establishing the cause of neonatal cholestasis is an
urgent matter. The aim of this study was to report on the prevalence and mortality of the
diverse disorders causing neonatal cholestasis in an academic center in Germany.
Methods: Clinical chemistry and cause of disease were retrospectively analyzed in 82
infants (male n=42, 51%) that had presented with neonatal cholestasis to a tertiary
medical center from January 2009 to April 2013.
Results: Altogether, 19 disorders causing neonatal cholestasis were identified. Bil-
iary atresia was the most common diagnosis (41%), followed by idiopathic cases
(13%), progressive familial intrahepatic cholestasis (PFIC, 10%), cholestasis in preterm
infants (10%), α1AT deficiency, Alagille syndrome, portocaval shunts, mitochondriopa-
thy, biliary sludge (all 2%), and others. Infants with biliary atresia were diagnosed
with a mean age of 62 days, they underwent Kasai portoenterostomy ~66 days after
birth. The majority of these children (~70%) received surgery within 10 weeks of age
and 27% before 60 days. The 2-year survival with their native liver after Kasai pro-
cedure was 12%. The time span between Kasai surgery and liver transplantation
was 176±73 days. Six children (7%), of whom three patients had a syndromic and
one a non-syndromic biliary atresia, died prior to liver transplantation. The pre- and
post-transplant mortality rate for children with biliary atresia was ~12 and ~17%,
respectively.
Conclusion: Neonatal cholestasis is a severe threat associated with a high risk of compli-
cations in infancy and it therefore requires urgent investigation in order to initiate life saving
therapy. Although in the last 20 years new causes such as the PFICs have been identified
and newer diagnostic tools have been introduced into the clinical routine biliary atresia still
represents the major cause.
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INTRODUCTION
Neonatal jaundice lasting longer than 14 days after birth is unusual.
In some of these infants it is associated with breast feeding (1),
but cholestasis must always be excluded by measurement of the
conjugated bilirubin in addition to the total bilirubin. Neona-
tal cholestasis is a serious condition requiring immediate further
Abbreviations: α1AT, alpha 1-antitrypsin; AFP, alpha-fetoprotein; ALP, alka-
line phosphatase; ALT, alanine aminotransferase; ANA, anti-nuclear antibod-
ies; AST, aspartate transaminase; ATIII, antithrombin III; ATT, α1-antitrypsin
deficiency; BA, biliary atresia; CF, cystic fibrosis; CMV, cytomegalovirus; EBV,
Epstein–Barr virus; ECG, electrocardiogram; ERCP, endoscopic retrograde cholan-
giopancreatography; GGT, gamma-glutamyltransferase; HAV, hepatitis A virus;
HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular car-
cinoma; HPS, hepatopulmonary syndrome; HSV, herpes simplex virus;IgA,
investigation because it may be due to life-threatening disorders
that must be addressed early in order to rapidly initiate specific
treatment (2).
The incidence of neonatal cholestasis is ~1 in 2500 live births
(3, 4). It results from impairment in bile excretion, caused by
various disorders such as defects of intrahepatic production or
immunoglobuline A; IGF, insulin-like growth factor; IGFBP, insulin-like growth
factor binding protein; INR, international normalized ratio; LDH, lactate dehy-
drogenase; LKM-1, liver/kidney microsomal antibody; MRCP, magnetic reso-
nance cholangiopancreatography imaging; MRI, magnetic resonance imaging;
PFIC, progressive familial intrahepatic cholestasis; PTT, partial thromboplas-
tin time; SMA, smooth muscle antibody; TNP, total parenteral nutrition; TSH,
thyroid-stimulating hormone; US, ultrasonography; VLCFA, very long chain fatty
acids.
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transmembrane transport of bile, or a mechanical ductal obstruc-
tion preventing bile flow. Of the various conditions that can
present with neonatal cholestasis, biliary atresia is the most com-
mon cause throughout the world and has been reported to account
for one-third of the cases (5–7). Early diagnosis is particularly
important in biliary atresia because timely surgical intervention
with Kasai portoenterostomy correlates with better long-term
outcome and patient survival (8–10). However, the diagnosis of
cholestatic jaundice in neonates is often delayed and this may result
in a poor patient outcome.
Here, we report the retrospective analysis of 82 infants with
neonatal cholestasis who were presented to a single tertiary cen-
ter during a 4-year period. This report provides information on
the prevalence and mortality of the various causes of neonatal
cholestasis, the diagnostic algorithm, and the timing of specific
medical and surgical intervention in infants with biliary atresia in
this cohort.
PATIENTS AND METHODS
PATIENT COHORT
A cohort of infants referred with the diagnosis of neonatal
cholestasis during a 4-year period from January 2009 to April 2013
to Essen, a tertiary medical center in western Germany, was retro-
spectively analyzed. Fifteen children referred from Eastern Europe
(Russia n= 1, Czech Republic n= 3, Hungary n= 11) during this
period were excluded for demographical reasons. These infants
were already diagnosed for neonatal cholestasis, those with biliary
atresia received a hepatoportojejunostomy in their home countries
and were transferred solely for the liver transplantation.
Neonatal cholestasis was defined as neonatal prolonged jaun-
dice with conjugated hyperbilirubinemia exhibiting a conjugated
(direct) bilirubin of more than 1 mg/dL (in combination with
a total bilirubin of <5.0 mg/dL or a direct bilirubin fraction of
>20% of the total). After 4 weeks, a direct bilirubin >0.2 mg/dL
was used as a cut-off value. All cholestatic infants received imme-
diate supplementation with lipid-soluble vitamins and parenteral
vitamin K supplement in case of coagulopathy.
STANDARD DIAGNOSTIC WORK-UP FOR CONJUGATED
HYPERBILIRUBINEMIA
Infants transferred with neonatal cholestasis underwent a stan-
dard diagnostic protocol, which included a detailed history and
physical examination, hematological, biochemical and serological
investigations, imaging procedures, and liver biopsy. All medical
interventions and laboratory diagnostics as well as the clinical pro-
cedures were performed in accordance with the declaration of
Helsinki.
Clinical standard procedures such as a precise physical exam-
ination (e.g., facial dysmorphic stigmata in Alagille syndrome),
pulse oximetry, abdominal ultrasonography, echocardiography,
ECG, and thoracic X-ray (butterfly vertebrae) were performed
in all children. Full blood cell count (including reticulocytes), a
blood microscopy, clinical chemistry including direct and indi-
rect bilirubin, serum aminotransferases (ALT, AST, and GGT),
albumin, electrolytes, creatinine, urea, uric acid, iron level, fer-
ritin, transferrin saturation, creatinkinase, lipase, alpha fetopro-
tein, triglycerides, cholesterol, immunoglobulins (IgM, IgG, and
IgA), serum bile acids, and a venous blood gas analysis were per-
formed in each patient. In cases of anemia, serum levels of LDH
and haptoglobin were determined and a direct Coombs test was
performed in order to differentiate in between immune and non-
immune mediated hemolysis. Coagulation parameters including
INR, aPTT, fibrinogen, and antithrombin III were assessed in each
patient. To exclude an infectious cause for cholestasis, a virolog-
ical analysis of all hepatotropic viruses (e.g., CMV, EBV, HSV,
HAV, HBV, HCV, Parvovirus B19, and others) as well as bacter-
ial and parasitic causes were considered. Endoscopic retrograde
cholangiopancreatography (ERCP) was performed in infants with
neonatal cholestasis, acholic stool for more than 7 days and a small
or even absent gallbladder in ultrasonography.
Since cystic fibrosis and alpha-1-antitrypsin (α1AT) deficiency
can mimic extrahepatic biliary atresia, both disorders were also
excluded before ERCP procedure. Cystic fibrosis was diagnosed by
determination of fecal elastase or immunoreactive trypsin (infants
younger 4 weeks of age). α1AT levels were determined in serum
and if reduced the deficient variant of the α1AT protein was
identified by protease inhibitor (PI) typing using polyacrylamide
isoelectric focusing (PI-M, PI-S, PI-Z alleles) (11).
In cases, biliary atresia was unlikely or excluded the follow-
ing tests were performed: to rule out an endocrinological cause,
morning cortisol level, IGFBP3, IGF1, and TSH plus free thyrox-
ine and triiodothyronine were assessed. Metabolic diseases were
diagnosed by determining urinary and serum amino acid pro-
files (to detect, e.g., tyrosinemia type I), organic acids in urine
(e.g., methylmalonic or propionic acidemia), acylcarnitine profile
in blood (fatty acid oxidation disorders), VLCFA levels (perox-
isomal disorders such as Zellweger’s syndrome), serum glucose
and lactate (pre- and postprandial to detect mitochondrial dis-
orders), and ammonium in plasma (urea cycle disorders such as
ornithine transcarbamylase deficiency). The investigation for car-
bohydrate metabolism disorders (e.g., galactosemia) is included
in the newborn screening panel. These metabolic studies were all
performed at the Laboratory for Metabolic Diseases, University
Hospital Heidelberg, Germany. To achieve the diagnosis of inher-
ited disorders of bile acid synthesis, urinary cholanoids (bile acids
and bile alcohols) were analyzed as reviewed by Clayton et al.
(12). A bone marrow aspiration was performed in infants with
splenomegaly if a metabolic disease (e.g., Gaucher or Niemann–
Pick disease), leukemia/lymphoma or histiocytosis was suspected.
Since autoimmune mediated cholestasis is a very rare cause, levels
of ANA, anti-dsDNA, and anti-Ro/SSA antibodies were deter-
mined in neonates either from mothers with a previous history
of systemic lupus erythematodes or as a last diagnostic option
before terming it idiopathic.
Liver biopsy was carried out in all patients except in those
infants that had unequivocal findings on other tests, especially
ERCP. The liver biopsy was examined with standard histology
and electron microscopy (storage diseases), immune histology (to
diagnose PFIC I–III, Professor R. Kubitz, Dusseldorf, Germany),
and – if clinically suspected – also for respiratory chain disorders
(shock frozen biopsy, MGZ, Munich, Germany). For histological
diagnosis of biliary atresia, standard criteria (e.g., bile ductular
proliferation, portal tract fibrosis, and bile plugs in portal triads)
were used (13). Neonatal giant-cell hepatitis (NGCH) was defined
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FIGURE 1 |The various disorders that led to neonatal cholestasis and the proportion of patients of each entity (%) of a cohort of 82 infants at a single
tertiary medical center.
as intrahepatic cholestasis with presence of characteristic giant-
cell lesions and idiopathic cases when no other detectable cause
was identified.
ERCP PROCEDURE
A pediatric videoendoscope with an outer diameter of 7.5 mm was
used for ERCP (Olympus PJF160 7.5, Olympus Co., Tokyo, Japan).
Informed consent was obtained from all parents. All examina-
tions were performed under general anesthesia with continuous
monitoring of vital functions. The children received intravenous
antimicrobial therapy for at least 24 h after cholangiography to
prevent persistent bacteremia and cholangitis. Blood cell count
and clinical chemistry were assessed 4–6 h after ERCP, whilst serum
amylase and lipase were routinely measured the following day.
STATISTICAL ANALYSES
The data analysis includes descriptive statistics of means with
standard deviations, medians, and ranges. Patient groups were
compared using the Mann–Whitney U test. All analyses were
performed using GraphPad Prism V5.0a. A p value <0.05 was
considered statistically significant.
RESULTS
PATIENT DEMOGRAPHICS
A total population of 82 infants (male n= 42, 51%) was assessed
within the period of analysis. In the majority of children (n= 49,
60%) the diagnosis was already secured: these children were
referred for further treatment and/or liver transplantation. Thirty-
three infants (40%) with cholestasis of unknown origin were
transferred from local community hospitals for further diagnostic
work up in our institution.
Of the total cohort, the mean age at initial referral to our cen-
ter was 71± 81 days (range 5–558 days). Most (87%) of these 82
children were referred from hospitals within 250 km of Essen,
other than one child from Munich (640 km distance). The most
common underlying liver disease was biliary atresia (n= 34; 41%)
followed by idiopathic cases (n= 11; 13%), progressive familial
intrahepatic cholestasis (PFIC, n= 8; 10%), and cholestasis sec-
ondary to total parenteral nutrition in preterm infants (n= 8;
10%). Among the 34 children with biliary atresia 4 (12%) had
a syndromic variant defined by polysplenia, a situs inversus, or
unusual vascular anomalies such as absence of an inferior vena
cava and a preduodenal portal vein. Among the eight infants diag-
nosed for PFIC, seven suffered from subtype II and one infant
from type III. The onset of cholestasis in preterm infants was in
the majority of the cases early after birth, in three cases it occurred
time-delayed (67± 23 days). None of these infants had neona-
tal (bacterial or viral) infections. Neonatal cholestasis in preterm
infants was regressive in all cases. Laboratory chemistry normal-
ized 160± 87 days after birth (median 149, range 85–338 days).
More detailed information on other disease entities is shown in
Figure 1.
Infants with neonatal cholestasis of unclear origin that had been
referred for diagnostic work-up to our center (n= 37) had biliary
atresia (n= 12; 32%) followed by idiopathic cases (n= 9; 24%),
PFIC (n= 3; 8%), cholestasis secondary to total parenteral nutri-
tion in preterm infants (n= 3; 8%), giant-cell hepatitis (n= 8,
27%), Alagille syndrome, biliary sludge, α1AT deficiency, cystic
fibrosis, Gaucher’s disease, and congenital neonatal diarrhea (each
n= 1, 3%, Figure 2).
BILIARY ATRESIA: AGE AT HEPATOPORTOENTEROSTOMY AND AT LIVER
TRANSPLANTATION
The mean age at initial referral of infants with biliary atresia was
37± 30 days (median 32, range 2–110 days) and when referred to
our center the children were 107± 112 days (median 82, range
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FIGURE 2 |The causes of neonatal cholestasis and the proportion of patients of each entity (%) of a cohort of 37 infants that were initially referred
with unclear cholestasis to the University Children’s Hospital Essen.
30–558 days) old. Again, most of the children (65%) were referred
from hospitals within an area of 250 km around Essen: Essen
(n= 4), Cologne (n= 6), Krefeld (n= 4), Duisburg (n= 2), Moers
(n= 3), Dortmund (n= 3), and others. The most distant center
was Munich (n= 1).
Infants were diagnosed for biliary atresia with a mean age
of 62± 16 (median 60 days, range 32–81 days); they received a
hepatoportoenterostomy with a mean age of 66± 24 days (median
60 days, range 37–146 days). The 2-year survival with their native
liver after Kasai procedure was 12% (4/34 children). The time span
between Kasai surgery and liver transplantation was 173± 75 days
(median 155, range 80–359 days). The mean age at liver trans-
plantation in children with biliary atresia was significantly earlier
(229± 77 days, median 222, range 87–441 days) compared to all
other cases of neonatal cholestasis (525± 240 days, median 538,
range 241–783 days; p< 0.01).
OUTCOMES OF ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY
In our hospital, ERCP was performed in 22 patients with sus-
pected biliary atresia (see Table 1). In 10 children biliary atresia
was excluded by cholangiography (extrahepatic biliary ducts with-
out pathologic findings in 9, sclerosing cholangitis in 1). In 12
children, biliary atresia was either confirmed by typical morpho-
logic changes seen by cholangiography (n= 6) or suspected due
to absent opacification of extrahepatic biliary ducts after injection
of contrast medium (n= 6). In the six cases with inconclusive
ERCP, additional diagnostic procedures were performed: One
patient was diagnosed by hepatobiliary scintigraphy and biopsy
and three patients by an intraoperative cholangiography. In the
remaining two, unequivocal liver histology plus the detection of
a dysplastic gall bladder and increased subcapsular hepatic arte-
rial perfusion on ultrasonography led to the diagnosis of biliary
atresia.
The mean age of investigated children suspected for BA was
50± 30 days (median 43, range 17–126) days and mean weight was
4.2± 1.0 kg. The average procedure time was 25 min. The overall
complication rate was low (9%, n= 2). Out of 22 children that
underwent ERCP, one suffered from relevant intramural duode-
nal bleeding and received red blood cell transfusion (15 mL/kg).
Another child was reintubated and treated with dexamethasone
because of respiratory insufficiency caused by post-interventional
laryngotracheal swelling. We observed no cases of post-ERCP
pancreatitis.
MORTALITY PRE- AND POST-LIVER TRANSPLANTATION
Children were considered for liver transplantation when they
showed liver synthesis insufficiency, hyperbilirubinemia, hypoal-
buminemia, dystrophy, clinical sequelae of portal hypertension
such as diuretic resistant ascites, and/or recurrent esophageal
variceal bleeding. Thirty of the 82 children with neonatal cholesta-
sis required liver transplantation within the period of the study.
Biliary atresia was the most frequent indication for transplanta-
tion (77%, n= 23). Six children among the total study population
died before liver transplantation was possible (7%). Of those, three
had syndromic variants of BA with malformations such as Aber-
nethy malformation, a congenital heart defect (double outlet right
ventricle, DORV), and a Fallots tetrad, one with non-syndromic
biliary atresia, one was a preterm infant with a complex mal-
formation syndrome and the other had a Zellweger syndrome.
The pretransplant mortality rate for children with biliary atresia
was ~12 vs. 4% of children with other disorders causing neonatal
cholestasis (Figure 3).
Four children deceased after transplantation: all had biliary
atresia, they received Kasai surgery without sufficient biliary
drainage 59, 66, 84, and 97 days after birth, respectively. All
were suffering from hepatopulmonary syndrome (HPS). In these
children, transplantation was performed within 10–19 days after
diagnosis of HPS.
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In summary, of 82 children with neonatal cholestasis 10 died in
the longitudinal course either before or after liver transplantation.
The majority of this subgroup with a poor outcome had biliary
atresia (n= 8), of which four patients had a syndromic BA variant.
DISCUSSION
A variety of disorders can present with cholestasis during the
neonatal period with biliary atresia as the most frequent cause
FIGURE 3 | Mortality pre- and post-LTX in biliary atresia (BA) and other
disorders causing neonatal cholestasis. The bar graph shows the
proportion of deceased children before and after liver transplantation (%).
Absolute patient numbers are printed in bold inside the bar graph segments.
Table 1 | Results of the ERCP procedure and final diagnoses.
Patient No. Diagnosis after ERCP Final diagnosis
1 Normal biliary tract Idiopathic
2 Inconclusive Biliary atresia
3 Normal biliary tract α1ATD
4 Inconclusive Biliary atresia
5 Normal biliary tract CF
6 Inconclusive Biliary atresia
7 Biliary atresia Biliary atresia
8 Normal biliary tract Idiopathic
9 Normal biliary tract Idiopathic
10 Biliary atresia Biliary atresia
11 Biliary atresia Biliary atresia
12 Primary sclerosing
cholangitis
Primary sclerosing
cholangitis
13 Inconclusive Biliary atresia
14 Inconclusive Biliary atresia
15 Inconclusive Biliary atresia
16 Biliary atresia Biliary atresia
17 Normal biliary tract Idiopathic
18 Normal biliary tract Biliary sludge
19 Biliary atresia Biliary atresia
20 Normal biliary tract Idiopathic
21 Biliary atresia Biliary atresia
22 Normal biliary tract CESD
Indication for the ERCPwas the presence of a pale, discolored stool, and an incon-
clusive ultrasonography failing to identify the gallbladder. Inconclusivemeans that
an unequivocal cholangiogram was not obtained during the procedure. CESD,
cholesteryl ester storage disease.
and idiopathic cases as the second common entity. A previous
study reported that 35% of infants with neonatal cholestasis had
biliary atresia and 30% were considered as idiopathic cases hav-
ing neonatal hepatitis (5). Other causes included α1AT deficiency
(17%), congenital viral infections (9%), Alagille syndrome (6%),
and choledochal cysts (3%). Almost 25 years later, this retrospec-
tive study confirms these data in part since biliary atresia accounted
for about 41% of all infants with neonatal cholestasis that were
referred to our hospital (Figure 1; Table 2).
In contrast to Mieli-Vergani (5), however, the percentage of
infants diagnosed with idiopathic cases is lower in the current
cohort (13 vs. 30%). This is likely due to the introduction of new
diagnostic tools that enable the detection of previously unrecog-
nized conditions. Rates of PFIC and TPN-induced cholestasis have
been underestimated in recent years as these disorders were not
described in previous demographic studies (Table 2). PFIC was
identified in 10% of the cases in this cohort, which is in line with
a previous reported empirical evidence of 10–15% of children
with neonatal cholestasis (20). The true incidence is not precisely
known but is estimated to be 1/50000–1/100000 births (20). Sub-
types 1 and 2 represent two-thirds and PFIC3 the remaining third
of cases with PFIC (21). Although to date three types of PFIC have
been identified (20), only the subtypes PFIC2 (n= 7) and PFIC3
(n= 1) were diagnosed in this cohort. In addition, the prevalence
of α1AT deficiency in the current cohort is low compared to pre-
vious reports identifying α1AT deficiency as the third common
cause among Caucasians (7).
Recently, molecular genetic tests became available to diagnose
the Alagille syndrome, PFIC I-III, and α1AT deficiency (22). These
tests have been reported to efficiently identify disease-causing
mutations and thus represent an adjunct alternative to timely clear
up the cause of cholestasis. Moreover, a more frequent genetic
testing for ATP8B1, ABCB11, and ABCB4 would generally iden-
tify more cases of PFIC because the immunostaining may namely
recognize the relevant proteins but does not detect a loss function
mutation – a reason why PFIC may be underdiagnosed in this and
current other studies. It thus can be expected that genetic testing
will imply the potential to expand the PFIC group among cases of
neonatal cholestasis in future studies. In preterm infants, neonatal
cholestasis was regressive in all cases. The cause for the develop-
ment of neonatal cholestasis in these children remains speculative.
The majority of preterm neonates developed cholestasis early after
birth (63%), a point of time when total parenteral nutrition was
just initiated. Alternatively, prematurity in combination with peri-
natal stress and/or asphyxia as the worst case may have resulted
in hepatic dysfunction leading to the perinatal onset of neonatal
cholestasis and may represent a potential causal factor for a gener-
ally benign and reversible cholestasis in preterm and also at term
neonates (23).
In this study, biliary atresia represents by far the most frequent
disorder causing neonatal cholestasis (Figure 1; Table 2). How-
ever, this study has a limitation. The relative incidences reported
here but also in other previous studies (6) need to be handled care-
fully, since they represent retrospective analyses of single tertiary
pediatric transplant centers. The subanalysis of our cohort demon-
strates that the study group includes two different groups – one
part is the local region’s infants with cholestasis undifferentiated
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Table 2 |The most common disorders causing neonatal cholestasis of the current study compared to those reported in the last 25 years.
Study Patients Country BA IC Metabolic, PFIC Preterm Infection Alagille Miscellaneous
(%) (%) endocrine, (%) (%) (%) (%) (%)
genetic (in%)
Hoerning et al. (14) 82 Germany 41 13 9 10 10 1 2 14
Lee et al. (15) 146 Malaysia 29 38 1 4 5 14 1 8
Aanpreung et al. (16) 252 Thailand 22 23 10 – 18 10 – 17
Bazlul Karim and Kamal (17) 62 Bangladesh 26 24 5 – – 36 2 7
Stormon et al. (18) 205 Australia 20 25 23 – 20 9 3 0
Yachha et al. (19) 60 India 55 12 3 – – 8 3 19
Mieli-Vergani et al. (5) 147 England 35 31 17 – – 9 6 2
Biliary atresia (BA) and idiopathic cases (IC) are the most common underlying cause of neonatal cholestasis in all studies. Metabolic disorders include genetic and
endocrinological causes.
and for further investigation at initial referral, and the second
a selected group containing already diagnosed children referred
from a wider area for further treatment and/or transplantation
(Figures 1 and 2). The latter subset of the group does bias the
incidence and mortality of disorders of the whole population
to a certain extent because children referred from other centers
may represent a grouping of more severe cases whereas some of
the cases with more benign cases of neonatal cholestasis would
not have been referred. Therefore, the severity of diseases may
be skewed toward a more severe spectrum of possible causes of
neonatal cholestasis (e.g., biliary atresia) that may generate the
differences in the incidences of other population-based studies.
On the other hand is the fact that the Children’s Hospital Essen
is located in one of the biggest congested urban area of Ger-
many containing over 5 million habitants. The catchment area
is small and the majority of the children (87%) that were referred
to our hospital with neonatal cholestasis were from community
hospitals from cities within an area of 250 km. Although the con-
sideration of a catchment area may not completely abrogate a
possible skewing toward more severe disorders, these children with
neonatal cholestasis represent a homogenous population within
a well-defined area of West-Germany. The differences with other
published series, namely the decrease of idiopathic cases of neona-
tal cholestasis and the increase of PFIC, may thus be caused at
least in part by an increased knowledge of new diagnoses and
improvements of the diagnostic work-up.
Neonatal cholestasis is a severe disorder in early childhood
with a pretransplant mortality that is not negligible. Especially
for children with biliary atresia it was about 12%. Biliary atresia
was the most frequent disorder in our and previously reported
cohorts (6, 24) leading to liver transplantation. Although only
infants with biliary atresia died after transplantation in our cohort
the intraoperative complications could have also affected infants
with other causes of neonatal cholestasis. The majority of those
infants that died before liver transplantation had disorders with
an unfavorable prognosis (three with syndromic variants of bil-
iary atresia, one with complex malformation syndrome, and one
with Zellweger’s syndrome), only one child had a non-syndromic
biliary atresia. However, the fact that syndromic variants seem
to carry a higher complication rate may depend on the small
series as previous multi-center studies did not find a difference
in between syndromic and non-syndromic variants of biliary
atresia (25, 26).
It is the late referral of children with biliary atresia that is widely
suggested to be accountable for an increased mortality (26–29)
since the success rate of the Kasai procedure is closely associ-
ated with the age at the time of surgery (9, 10, 30). Besides age
at hepatoportoenterostomy several other risk factors for a failure
of Kasai surgery have been described and include histologic fea-
tures (small or absent bile ducts at the portal plate) and recurrent
episodes of cholangitis (13). It is reported that children with bil-
iary atresia referred for surgery before 60 days of age do markedly
better with a reestablishment of bile flow in more than 80% than
those older than 90 days at the time of operation (5, 27, 31–33).
This had been shown both in the short-term and in the long-term
course (9, 34, 35). The earlier surgery was performed, the later
a liver transplantation was usually needed (8). In the short-term,
infants that earlier received a Kasai procedure less frequently devel-
oped intrapulmonary vascular dilatations, a condition preceding
the development of a HPS (14). In the long-term, every second
infant with biliary atresia who underwent surgery <30 days of
age was still living with his/her own liver 10 years later compared
to 15% of those treated after 90 days of age (34). In our cohort,
infants with biliary atresia were initially presented to a secondary
health care provider with a mean age of 37 days, the mean age at
diagnosis was 62 days. This is in line with the average age at diag-
nosis of biliary atresia, e.g., in the USA (36) and Germany (37)
(~60 days). The Kasai procedure was performed soon after diag-
nosis at a mean age of 66 days demonstrating that the late diagnosis
of biliary atresia caused the delay in an appropriate treatment. The
majority of the children in this cohort (~70%) underwent surgery
before 10 weeks of age and only 27% before 60 days. Hence, cor-
rective surgery within the first 2 months of age is still by far not
the routine although substantial efforts have been undertaken to
overcome this problem (38, 39).
Among these it is a current endeavor to centralize the services
and treat children with biliary atresia in few experienced centers
in order to increase surgical success and survival with the native
liver (26). A recent large German multi-center study confirmed a
relation between outcome and experience of the surgical center
and reported a 2-year survival of 20% with their native liver (40).
The 2-year survival with the native liver was even less (12%) in our
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cohort. However, it is important to emphasize that the numbers
of this study are biased by the fact that a majority of children with
biliary atresia had a history of a failed Kasai procedure and were
referred to our center for the purpose of liver transplantation.
The initial and timely detection of biliary atresia is currently
and in future will still be a domain of the primary health care
provider and depends on the recognition of prolonged jaundice
and abnormal stool and/or urine color. It is often challenging as a
substantial group of breast fed newborns (ca. 15%) develop benign
neonatal jaundice (1) and infants with biliary atresia often appear
well during the first 3 weeks after birth. In Germany, at 4–6 weeks
of age a visit to a pediatrician is generally recommended and sup-
ported by the governmental health insurance system. A routine
dipstick test for urinary bilirubin excretion and/or the use of a
stool color card at this visit would be an additional non-invasive
and simple check to identify cholestatic infants. Furthermore, both
types of biliary atresia, the fetal type with early onset and the peri-
natal type with later onset during the second to fourth weeks of
life (6), would be detected at this time point. However, within the
last three decades (5) no essential progress had been achieved in
early identification of biliary atresia. There is still an urgent need to
increase the awareness of prolonged jaundice caused by neonatal
cholestasis and of its severity.
When biliary atresia is suspected, ERCP may serve as a reliable,
accurate and safe additional beneficial diagnostic tool in unclear
cases of children with non-pigmented stool (37, 41, 42). Here,
ERCP clarified the diagnosis in 73% of the cases where biliary
atresia was suspected (16/22 infants). Both the low complication
rate as well as the average procedure time of ERCP was in line with
previous studies (37, 43). Hence, ERCP (if conclusive) may repre-
sent a safe method expanding the diagnostic repertoire especially
4–6 weeks after birth when histological findings are sometimes not
unequivocal (2, 44). Although it is not generally recommended
yet we would therefore encourage performing an ERCP and liver
biopsy 4–6 weeks after birth at latest if acholic stools are persist-
ing and biliary atresia is suspected. The ERCP procedure however
should be performed by operators specifically skilled in pediatric
patients in an expert tertiary center in order to guarantee a safe
and reliable procedure that then enables to detect biliary tract
abnormalities (e.g., biliary atresia or choledochal cysts) with high
sensitivity and specificity.
In conclusion, a variety of hepatobiliary disorders with biliary
atresia as the major cause can present with cholestasis during the
neonatal period. A systemic approach is the key to reliably achieve
a rapid diagnosis in order to initiate disease-specific and in many
cases life saving therapy. Therefore, any infant presenting with
prolonged jaundice at 14 days of age with or without acholic stool
must be evaluated by determination of the fractionated bilirubin
and if elevated referred to a subspecialist for pediatric hepatology
as soon as possible in order to confirm or rule out biliary atresia
and other treatable disorders.
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